U.S. Continuous Renal Replacement Therapy Market Size To Hit USD 1,396.69 MN By 2034
The U.S. continuous renal replacement therapy market size was exhibited at USD 805.94 million in 2024 and is projected to hit around USD 1,396.69 million by 2034, growing at a CAGR of 6.3% during the forecast period 2025 to 2034.
| Report Coverage | Details |
| Market Size in 2025 | USD 805.94 Million |
| Market Size by 2034 | USD 1,396.69 Million |
| Growth Rate From 2025 to 2034 | CAGR of 6.3% |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Segments Covered | Product, Modality |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Key Companies Profiled | Baxter; B. Braun Melsungen AG; Fresenius Medical Care AG; Medtronic; Asahi Kasei Medical Co., Ltd.; Nipro Corporation |
The growth of the U.S. market can be attributed to the rising incidence of Acute Kidney Injury (AKI) and sepsis, rapid increase in the number of hospitals and urgent care centers, rising hospital admission rate, and constant product launches by prominent market players. In addition, the COVID-19 outbreak has resulted in significant demand for continuous renal replacement therapy (CRRT) in the U.S. Owing to this, the market has witnessed regulatory support from various government authorities and a rise in financial incentives. These factors are expected to contribute to the growth of the U.S. market during the forecast period.
The rising incidence of AKI is a key factor driving the demand for CRRT in the U.S. For instance, according to the National Kidney Foundation, Inc., 37 million people in the U.S., i.e., more than one in seven adults, are estimated to be affected with chronic kidney disease. Moreover, in the past several years, the incidence of AKI requiring Renal Replacement Therapy (RRT) has increased by about 10% annually.
Furthermore, according to another research study published in Wolters Kluwer Health, Inc., the rate of CRRT used in ICU patients in the U.S. is about 244/1,433 (17%). For such severely ill patients, CRRT is the preferred and most common form of acute RRT used in ICUs. Thus, owing to the aforementioned factors, the adoption of CRRT is expected to grow at a rapid rate in this country.
Current CRRT technology has enabled comprehensive technological data analysis and appropriate feedback. These advancements have led to a thorough analysis of prescription and delivery patterns, which has positively impacted clinical outcomes from a quality assurance perspective. Latest CRRT machines enable automated data collection and utilize uniform terminology that allows for cross-institutional comparisons.
Several key players operating in this market have launched advanced CRRT machines that feature these technologies. For instance, Prismaflex System developed by Baxter helps to provide automatic adjustments and instant visual feedback regarding the treatment. It is integrated with Electronic Medical Records (EMR) connectivity and eliminates manual recording and transfer of treatment data. Such technological advancements are likely to further accelerate the market growth in the U.S.
The growing investments in healthcare by the government and private sector in the U.S. are supporting the market growth. According to statistics published in CMS.gov, healthcare expenditure in the U.S. increased by 4.6% in 2023, reaching USD 3.8 trillion per person, which accounted for a 17.7% share of the nation’s GDP.
The current COVID-19 outbreak is expected to have a substantial impact on the U.S. market. The pandemic has significantly increased the demand for RRT across the U.S. In the pre-COVID-19 period, RRT was used to treat around 23,105 patients for AKI each year. The requirement for RRT among COVID-19 patients appears to be 5 times higher, i.e., 4.9%, than that in historical populations (0.9%). In community cohort datasets, 5%-15% of individuals hospitalized with COVID-19 required dialysis assistance. The population using CRRT increased by 370% in select U.S. locations compared to usual levels.
Moreover, several U.S. states are expected to face CRRT shortages during the COVID-19 pandemic. As per the same source, in the U.S., the shortage of 1088 CRRT machines was expected during the first 6 months of the pandemic, with demand outpacing supply in up to eight states. Thus, the growing demand for RRT imposed a burden on the delivery of all dialysis therapies across the U.S. healthcare system.
In addition, individual practitioners, hospitals, and local communities were able to respond to the growing demand and limited availability of RRT equipment and consumables owing to manufacturers' capacity to increase the supply. For instance, in April 2021, Baxter received the U.S. FDA Emergency Use Authorization (EUA) for its Oxiris Blood Purification Filter set for COVID-19 patients admitted to the ICU with confirmed/imminent respiratory failure in need of blood purification therapy.
In 2024, the liquids segment dominated the U.S. market with a revenue share of over 60.0%. The liquid segment comprises dialysates, renal replacement fluids, anticoagulants, and saline. Increasing demand for CRRT in the treatment of hemodynamically unstable patients and the growing number of manufacturers supplying dialysate and replacement fluids for RRT are among factors contributing to the segment growth.
Moreover, the growing number of manufacturers supplying dialysate and replacement fluids for RRT are other key factors fueling the segment growth. For instance, as per a research study published in Kidney360 journal, due to the COVID-19 pandemic, the demand for bagged dialysate fluid, which is most commonly utilized in the ICU environment, increased significantly by 38% and continues to grow. To satisfy the growing demand for dialysis fluids, manufacturers expanded the output of bicarbonate-based solutions.
In addition, key players are receiving EUA for their replacement fluids and solutions. This factor is contributing to the segment growth. For instance, in August 2024, Baxter received FDA EUA for its replacement solution used for adult patients undergoing CRRT during COVID-19 treatment. Regiocit can be used with patients who are at a higher risk of bleeding during continuous dialysis.
The disposables segment is projected to expand significantly during the forecast period owing to the increasing use of hemofilter, fluids, charcoal filters, and other consumables in CRRT treatments. The disposables segment mainly includes disposable treatment kits/infusion kits, hemofilter, and bloodlines. These products are low-priced, used frequently, and of high quality.
Furthermore, consumables used during CRRT must be replaced after each setup to minimize contamination. Contaminated consumables such as recycled fistula needles can endanger a patient's life. As a result of a large replacement rate of consumables owing to low pricing, their demand is likely to increase, thereby promoting segment growth. Moreover, factors such as the increasing prevalence of AKI and the growing emphasis on effective CRRT among ICU patients are boosting the demand for disposables.
In 2024, the continuous venovenous hemodialysis (CVVHD) segment dominated the market with a volume share of over 31.0% in terms of procedure/treatment. The CVVHD treatment modality has high efficacy with low blood flows.
Moreover, the U.S. CRRT market for CVVHD is expected to grow due to the use of smaller, less invasive catheters and longer filter running times compared to convective treatment modalities. For instance, Ci-Ca CVVHD with Ultraflux EMiC 2 filter developed and manufactured by Fresenius Medical Care is an advanced CRRT therapy, combining the advantages of CVVHD with better removal of middle molecules while retaining essential plasma proteins such as albumin and cellular blood constituents. Such developments are expected to support the segment growth over the forecast period.
The continuous venovenous hemodiafiltration (CVVHDF) segment is expected to expand at the highest volume-based CAGR of 6.25% from 2025 to 2034. The increasing prevalence of fluid overload cases, which is frequently found in AKI patients in critical care units, is expected to propel the growth of the CVVHDF segment over the forecast period. Moreover, according to an article published by the American Society of Nephrology, congestive heart failure, which accounts for approximately 8% of all-cause mortality in patients at stages 4 & 5 of CKD, is associated closely with fluid overload, which is likely to increase the application of CVVHDF treatment procedure. These factors are further expected to fuel the segment growth over the forecast period.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the U.S. continuous renal replacement therapy market
By Product
By Modality
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers